drugset
drugset / Trial / NCT01498120

Long-Term Follow-Up Study for Safety, Efficacy and Tolerability of Rotigotine in Adolescents With Restless Legs Syndrome

NCT01498120 ↗

Phase 2 Completed 14 enrolled UCB BIOSCIENCES, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 2, multicenter, open-label, single-arm, optimal dose, long-term follow-up study of monotherapy administration of rotigotine transdermal patch in adolescents with Restless Legs Syndrome (RLS). This study will assess the long-term safety and tolerability of Rotigotine treatment in adolescents with RLS.

Timeline

Start
2011-12
Primary completion
2015-12
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Rotigotine Unknown 0.5 mg Other
Subject Rotigotine Unknown 1 mg Other
Subject Rotigotine Unknown 2 mg Other
Subject Rotigotine Unknown 3 mg Other

Indications

restless legs syndrome